Probiotic trial in Parkinson's disease patients, China
222 fecal/serum samples from Parkinson's disease patients in Weihai, Liaocheng, and Jinzhou, China, from a randomized, double-blind, placebo-controlled trial of Bifidobacterium animalis Probio-M8 probiotic supplementation alongside standard pharmacological therapy. machine-written summary
222 samples · 222 runs · CN · Age unknown · 2022 · 10.38 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 1,977 sample values (collection date, country, intervention, latitude, location locality, location region, longitude, subject id) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 222 sample values (antibiotic exposure) · PMC11684920, PMC9130297 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet · share metadata |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
Probiotic (live microorganisms; single strain or mixture) design randomized_controlled_trial · population neurological_psychiatric · Bifidobacterium animalis Probio-M8 vs placebo, 3 months, adjunct to PD drugs
“randomized, double-blind, placebo-controlled clinical trial” — abstract:35610236 (study level; per-sample arms are in the intervention column below)
longitudinal
74 of 74 people sampled more than once (222 samples; median 3, up to 3 per person) · follow-up median 3 mo (max 3 mo) · median interval between samples 46 d (time from timepoint labels). Schedule stated by the source: “stool and clinical measures at baseline (0d), 1 month, and 3 months; serum at 3 months” (time origin: intervention_start); stated follow-up 3 mo.
Each row is one person (36 shown of 74); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 201 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 222 | 100% | 222 | |||
| health_condition | 0 | 0% | ||||
| subject_id | 222 | 100% | 222 | |||
| antibiotic_exposure | 222 | 100% | 222 | |||
| collection_date | 222 | 100% | 222 | |||
| detailed_location | 222 | 100% | ||||
| intervention | 222 | 100% | 222 | |||
| latitude | 222 | 100% | 222 | |||
| location_locality | 222 | 100% | 222 | |||
| longitude | 222 | 100% | 222 | |||
| timepoint_label | 222 | 100% | 222 | |||
| location_region | 201 | 91% | 201 |
- Probiotics synergized with conventional regimen in managing Parkinson's disease. 2022 PMID 35610236 PMC9130297 own_data
- Secondary analysis reveals gut microbiota differences in patients with Parkinson's disease and/or cognitive impairment. 2024 PMID 39741952 PMC11684920 unsure
Archive description
Parkinson's disease has been improved to association with gastrointestinal symptoms and gut microbiota disorders, probiotics is considered as a technique for GI symptoms, while the regulative effect of probiotics on Parkinson's disease is limited. The supplementary treatment of Probio-M8 on Parkinson has been investigation.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.75. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site run.scientific_name · “feces metagenome”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN22185038 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | antibiotics within one month prior to this study |
| SAMN22185038 | collection_date | 2019-05-01/2020-10-30 | R1 | 0.90 | biosample.attribute:collection_date | 2019-05-01/2020-10-30 |
| SAMN22185038 | country | CN | R1 | 0.90 | sample.attr.geo_loc_name | China: Liaocheng |
| SAMN22185038 | intervention | placebo | R1 | 0.85 | biosample.attribute:description | description: Control |
| SAMN22185038 | latitude | 36.4600 | R1 | 0.90 | biosample.attribute:lat_lon | 36.46 N 115.99 E |
| SAMN22185038 | location_locality | Liaocheng | R1 | 0.85 | biosample.attribute:geo_loc_name | China: Liaocheng |
| SAMN22185038 | location_region | Shandong Sheng | R1 | 0.60 | biosample.attribute:lat_lon | 36.46 N 115.99 E |
| SAMN22185038 | longitude | 115.9900 | R1 | 0.90 | biosample.attribute:lat_lon | 36.46 N 115.99 E |
| SAMN22185038 | subject_id | LC09 | R1 | 0.70 | sample.name_rule:alias | Sample_LCA09 |
| SAMN22185038 | timepoint_label | baseline | R1 | 0.70 | sample.name_rule:alias | Sample_LCA09 |
Sequencing
222 runs over 222 samples · mean 10.19 Gbp per run (median 10.38 Gbp, total 2,261.25 Gbp; 222 runs with a base count) · layout PAIRED 222 · platform ILLUMINA 222 · models Illumina HiSeq 2500 (222) · 91% of runs with a Sandpiper profile · first public 2022-05-26
Authors (17)
Sun H first · Zhao F · Liu Y · Ma T · Jin H · Quan K · Leng B · Zhao J · Yuan X · Li Z · Li F · Kwok LY · Zhang S · Sun Z · Zhang J · Zhang H last · Shen X first
Help complete this project
2 of the 4 core fields are below 50% coverage: age_category, health_condition. Share metadata
Downloads
PRJNA769968.csv.gz (7.0 KB) · parquet (78.3 KB) — all 222 samples, every field with route and confidence · PRJNA769968_determinations.csv.gz (15.5 KB) — 2,199 evidence rows